51304-99-5 Usage
Uses
Used in Pharmaceutical Industry:
2,4-Bismorpholino-6-benzylamino-1,3,5-triazine is used as a potential drug candidate for the development of pharmaceuticals targeting specific biological pathways or diseases. Its structure and properties make it a valuable compound for medicinal chemists to explore its therapeutic potential.
Used in Chemical Production:
2,4-Bismorpholino-6-benzylamino-1,3,5-triazine may also be used in the production of specialty chemicals, where its unique chemical structure could contribute to the creation of novel compounds with specific applications.
Used in Organic Synthesis:
As a reagent in organic synthesis, 2,4-Bismorpholino-6-benzylamino-1,3,5-triazine could be employed in the synthesis of complex organic molecules, potentially leading to the discovery of new chemical entities with various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 51304-99-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,3,0 and 4 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 51304-99:
(7*5)+(6*1)+(5*3)+(4*0)+(3*4)+(2*9)+(1*9)=95
95 % 10 = 5
So 51304-99-5 is a valid CAS Registry Number.
51304-99-5Relevant academic research and scientific papers
Synthesis and antitumor evaluation of a novel series of triaminotriazine derivatives
Zheng, Mingfang,Xu, Chenghui,Ma, Jianwei,Sun, Yan,Du, Feifei,Liu, Hong,Lin, Liping,Li, Chuan,Ding, Jian,Chen, Kaixian,Jiang, Hualiang
, p. 1815 - 1827 (2008/02/03)
A series of triaminotriazine derivatives (compounds 5a-f, 6a-x, and 7a-g) was designed, synthesized, and evaluated for their inhibition activities to colorectal cancer (CRC) cell lines (HCT-116 and HT-29). Most of the synthesized compounds demonstrated moderate anti-proliferatory effects on both HCT-116 and HT-29 cell lines at the concentration of 10 μM. The inhibitory activities against HCT-116 and HT-29 cell lines were discussed to develop the structure-activity relationships of this new series. Compounds 6l and 6o exhibited prominent inhibition activities toward HCT-116, with IC50s of 0.76 and 0.92 μM, respectively. The in vivo antitumor studies and pharmacokinetics of compound 6l showed that it might be a promising new hit for further development of antitumor agents.
